Acute myeloid leukemia (AML) in first remission (CR1) with isolated NPM1 mutation (iNPM1m) is considered a good prognosis genotype, although up to one-third relapse. To evaluate the best transplant strategy, we retrospectively compared autologous stem cell transplantation (auto-SCT), related (MSD), and fully matched unrelated (MUD) allogeneic stem cell transplantation (allo-SCT). We identified 256 adult patients including 125 auto-SCT, 72 MSD, and 59 MUD.
and P = .13, respectively) and better LFS (P = .01 and P = .31, respectively). Age correlated with higher NRM (P < .01). Allo-SCT using MSD appears as a reasonable transplant option for young patients with iNPM1m AML in CR1. Auto-SCT was followed by worse RI and LFS, but similar OS to both allo-SCT modalities.
| INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) remains to date the best consolidation strategy in high-risk acute myeloid leukemia (AML), while autologous stem cell transplantation (auto-SCT) is a good alternative in chemosensitive and favorable AML. [1] [2] [3] [4] Risk stratification is mainly based on cytogenetics at diagnosis, but up to 50% of patients do not have a detectable clonal chromosomal abnormality. 5, 6 Nowadays, acquired gene mutations and deregulation of gene expression have been identified in AML and are currently integrated in the decision strategy. [7] [8] [9] Nucleophosmin (NPM1) is a shuttle protein that mainly acts as a tumor-supressor. Mutations in exon 12 of NPM1 have been found in up to 60% of patients with AML and normal or intermediate-risk
karyotype. The presence of these mutations, especially when a FLT3 mutation is absent, has been associated with a good response to chemotherapy and a better outcome, 10 which has been confirmed even in elderly patients. 11, 12 A donor versus no donor analysis showed no benefit of allo-SCT in AML patients with NPM1 mutations without FLT3-ITD in first remission (CR1) and it is currently recommended not to offer allo-SCT to these patients in early disease phase. 8 Many of those patients who experienced relapse can be salvaged with chemotherapy and undergo allo-SCT in second remission (CR2) with a relatively favorable outcome. 13 Nevertheless, the cumulative incidence of relapse in patients achieving CR1 after standard chemotherapy in isolated NPM1 mutated (iNPM1m) AML is still about 40%, and therefore, the best post-remission strategy is still debatable. 13 High dose chemotherapy followed by auto-SCT has been shown to decrease relapse incidence compared to conventional chemotherapy, but this benefit is mainly restricted to AML with good cytogenetics. 2, 14 Because of its intrinsic chemosensitivity, the same benefit might be expected for iNPM1m AML. Indeed, Ferrara et al. showed a significant advantage of high dose chemotherapy and auto-SCT in 35 AML patients with NPM1 mutations. 15 In another French study of 46 AML patients with iNPM1m, the authors did not find significant difference in terms of survival between patients who received allo-SCT or auto-SCT as consolidation therapy. 16 Considering less toxicity associated with auto-SCT, auto-SCT-based consolidation strategy appears as a good option in this molecular AML subgroup. 17 Although several groups have supported auto-SCT as the best consolidation in iNPM1m AML, the role of allo-SCT in this specific subgroup of patients has been recently revisited in two different studies. Röllig et al. showed a very good outcome after allo-SCT for iNPM1m AML in CR1, with a significant reduction of relapse in a donor versus no donor analysis despite a neat survival benefit. 18 Another retrospective study showed a much better survival when the allo-SCT is performed in CR1 compared to CR2. 19 Moreover, the existence of a specific T-cell response to NPM1 mutated cells has been suggested, which may contribute to a graft-versus-leukemia effect in the setting of allo-SCT. 20 Finally, NPM1 mutations appear as a suitable marker for minimal residual disease (MRD), allowing to detect patients at higher risk of relapse. 21, 22 Ivey et al. recently demonstrated that MRD evaluation after the second course of frontline chemotherapy is strongly associated with outcomes and may help to better identify patients with a high relapse risk who might benefit from allo-SCT in morphological CR1. 23 Nevertheless, in that study, allo-SCT was not able to overcome the negative impact of MRD, may be due to the quite low number of patients with positive MRD including in the study. In a further attempt to define the best transplantation approach for iNPM1m AML in CR1, we decided to conduct a retrospective study within the Acute Leukemia
Working Party (ALWP) of the EBMT comparing auto-SCT to allo-SCT using either a sibling donor or a well-matched unrelated donor.
| MATERIALS AND METHODS

| Patient selection and data collection
This is a retrospective study performed by the ALWP of the EBMT group. EBMT registry is a voluntary working group of more than 600 transplant centers, participants of which are required once a year to report all consecutive stem cell transplantations of their respective centers and follow-up. We first selected patients with an age equal to or over the age of 18 years and with a diagnosis of de novo AML trans- 3 | RESULTS
| Patients' characteristics
Patients' characteristics are summarized in Table 1 . A total of 256 patients has been allocated. One hundred twenty-five patients had an auto-SCT, 72 received SCT from their matched sibling donor Abbreviations: Auto, autologous; SCT, stem cell transplantation; MSD, matched sibling donor; MUD, matched unrelated donor; yo, year-old; N, number; M, male; F, female; TBI, total body irradiation; SC: stem cell; PB, peripheral blood; BM, bone marrow; CR, complete remission; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; TCD, T-cell depletion.
(MSD), and 59 from a 10/10 matched unrelated donor (MUD). Median age was quite similar across groups (Table 1) . Median follow-up time was significantly shorter for MUD-SCT as most of those transplantations have been performed more recently. Twenty four percent of the patients needed more than one cycle of induction therapy to achieve complete remission, which was not different between auto-and allo-SCT. NPM1-based MRD status at the time of SCT was available in 140 patients (55%), being detectable in 16% and 37% of patients of the auto-SCT group and allo-SCT group, respectively (P = .019). Total body irradiation (TBI) was part of the preparative regimen more frequently in the allo-SCT (Table 1 
| Non-relapse mortality and relapse incidence
The 2-year probability of NRM was 5% [95% CI: 2. In multivariate analysis, only MSD-SCT compared to auto-SCT but not MUD-SCT compared to auto-SCT was significantly associated with a decreased RI (P = .004) ( Table 2 ).
| Overall survival and leukemia-free survival
The 2-year probability of OS was 82.5% [95% CI: 77. were not associated with OS. No outcomes' differences were also found when the analysis was focused on patients in molecular remission in comparison to those patients not achieving molecular remission pre allo-SCT. In multivariate analysis, we confirmed that no factor correlated with OS ( Table 2 ). The main cause of death was disease- ( Figure 1D ). By allo-SCT modalities, MSD-SCT led to a significant better LFS than auto-SCT (P = .006), while MUD-SCT and auto-SCT showed similar LFS (P = .6). Age, interval from diagnosis to SCT, number of induction courses to reach remission, molecular status, performance status, and additional cytogenetic abnormalities were not correlated with LFS in univariate analysis. However, while in patients younger than 50-year-old, the 2-year LFS remained significantly bet- to auto-SCT but not MUD-SCT compared to auto-SCT was significantly associated with a better LFS (P = .01) ( Table 2 ).
| Engraftment, graft-versus-host disease, and second transplantation
All patient in the auto-SCT group engrafted, while engraftment results by the different conditioning strategies. 18 The question of the best transplantation approach in iNPM1m AML remains then unresolved. Our study showed indeed a very good anti-leukemic control in iNPM1m AML with allo-SCT using MSD. We observed an excellent 2-year LFS of 81% and a very low 2-year relapse incidence of 12%, which compared favorably with the inferior results obtained with auto-SCT. Of course, the retrospective nature of our study implements some selection bias as patients referred to MSD-SCT might have been highly selected. The low NRM of 7% observed after allo-SCT may reflect this selection process but may also be due to the improvement in supportive care in recent years. 27 However, iNPM1m patients are very sensitive to chemotherapy, which allowed them to access easily to CR1, without auto-SCT as a good treatment option in view of its lower NRM. 2, 4 Similarly, in acute promyelocytic leukemia (APL) in second remission, better outcomes were achieved with auto-SCT compared to allo-SCT. 32 Application of new conditioning regimens with better toxic profile and better anti-leukemic activity may even lead to improved Abbreviations: NRM, non-relapse mortality; RI, relapse incidence; OS, overall survival; LFS, leukemia-free survival; MSD, matched sibling donor; MUD, matched unrelated donor; abn, abnormalities; CR, complete remission; HR, hazard ratio; CI, confidence interval. results. 14, 33 Due to its intrinsic chemosensitivity, AML with iNPM1m might be expected to gain the same benefit from auto-SCT similar to CBF AML and APL. Indeed, in a small retrospective French study, allo-SCT, auto-SCT and chemotherapy provide the same LFS of about 60% in 46 iNPM1m AML patients. 16 In another EBMT retrospective study, LFS was 46% after auto-SCT in 66 patients with iNPM1m AML. recommending allo-SCT in CR1 for NPM1 mutated AML. 13 However, in a recent retrospective study by the EBMT performed in 156 patients with iNPM1m AML, allo-SCT performed in CR2 showed a significant worse 2-year LFS compared to allo-SCT in CR1 (51% vs 71%, P = .005). 35 In the latter study, type of donor (MSD vs MUD) was not associated with different LFS in multivariate analysis. If a survival benefit could not be demonstrated in our study, we cannot dismiss the excellent disease control obtained with MSD-SCT. Due to significant association between age and NRM, we may consider allo-SCT in CR1
only for young patients with iNPM1m AML as a therapeutic consolidation strategy if a MSD is available. Indeed, we showed a significant advantage of MSD-SCT over auto-SCT in patients younger than 50-year-old (P = .03), which was not that obvious in older patients (P = .09). The benefit of MSD-SCT in younger patients supports that age remains an important prognostic factor, although mainly confounded with other co-morbidities as previously demonstrated. 1, 36 However, such transplant-registry based study always lacks data on patients having received only chemotherapy as consolidation strategy.
The benefits of chemotherapy over transplant modalities are mainly featured by less secondary malignancy, less endocrine disorders and better quality of life. 37, 38 Previous studies comparing chemotherapy over auto-SCT and allo-SCT have reported similar LFS in the range of 60%-70%, 8, 16, 39 which remains close to the results we observed after auto-SCT and MUD-SCT. Nevertheless, the risk of late effects after transplant procedures should be integrated in the decision-making on post-remission therapies.
NPM1 mutation has been showed as a stable event in AML, which makes it a suitable marker for MRD monitoring. Persistent detection of NPM1 mutation after chemotherapy or allo-SCT has been constantly associated with higher relapse rate with different thresholds reported. 21, 22 In a recent study performed on 346 patients with NPM1 mutation, persistence of the mutation after the second cycle of chemotherapy was significantly associated with an increased risk of relapse.
Allo-SCT has been performed in 21 out of 46 patients with persistent NPM1 mutation but was not able to overcome the negative impact of MRD. 23 In our study population, we had 38 patients with persistent MRD at the time of transplantation. They showed a significant increasing risk of relapse without any impact on survival, independently of the type of transplant. Another study conducted by Balsat et al. showed that a 4-log reduction in NPM1 level after one cycle of chemotherapy was significantly associated with a good outcome, independently of the FLT3 mutational status. They also showed that allo-SCT was able to significantly improve survival in patient with poor molecular response, 40 which has been confirmed in another report. 41 However, in our cohort of 102 patients with complete molecular response, we still found a significant benefit of MSD-SCT over other transplant strategies. We did not find from the registry data any reason why those patients in molecular remission have been brought to allo-SCT, but they all obtained very good LFS. The small number of patients reported with persistent MRD in our study precludes any firm conclusion concerning the best consolidation strategy in this setting. Given the lack of standardization to detect MRD, as well as the different thresholds to define molecular remission in each center, it remains extremely difficult to analyze further this topic in a registry-based setting. Another limitation of our study is the lack of information about other co-occurring mutations, which may have further influenced the prognosis, such as DNMT3A, IDH1/IDH2, and TET2.
42-45
Auto-SCT has been favored in many studies based on the lower NRM but also on a better quality of life by avoiding the risk of GvHD and infections associated with allo-SCT. 14, 46 The rates of acute and chronic GvHD in our study were in the range of previously reported studies. This translates into a 2-year probability of GRFS of 58% after MSD-SCT, which is closer to the 2-year LFS after auto-SCT, even though a direct comparison is not statistically feasible. We may then suggest that the excellent results observed after MSD-SCT were somehow overestimate due to a decreased quality of life related to the presence of GvHD. Among the relapsed patients after auto-SCT, 41 patients received a second transplantation as part as the salvage therapy. If the 2-year OS was similar across transplant modalities, our study cannot capture the long-term effects of auto-SCT salvage by a second transplant procedure. Finally, the relative short median followup of our study does not allow us to analyze the risk of late relapse in patients still in remission 2 years after auto-SCT. 47 In conclusions, our retrospective study showed that allo-SCT using MSD is a suitable transplant option which should be discussed in young patients with iNPM1m AML in CR1. We can envision that quality of life may be decreased in those patients due to the development of GvHD, but on the other hand, auto-SCT expose patients to long-term effects and late relapse. Without an appropriate chemotherapy arm as comparator and without a significant benefit in terms of OS, MSD-SCT should only be retained as a potential strategy in young patients. The low number of patient with persistent disease included in our study precludes any firm conclusion on the role auto-and allo-SCT in this patient category. Future studies are needed to better define and standardize molecular response in order to better characterized and select the patients who may benefit from auto versus allo-SCT.
